2. Academic Validation
  3. Imidazopyrimidines, potent inhibitors of p38 MAP kinase

Imidazopyrimidines, potent inhibitors of p38 MAP kinase

  • Bioorg Med Chem Lett. 2003 Feb 10;13(3):347-50. doi: 10.1016/s0960-894x(02)01020-x.
Kenneth C Rupert 1,  James R Henry,  John H Dodd,  Scott A Wadsworth,  Druie E Cavender,  Gilbert C Olini,  Bohumila Fahmy,  John J Siekierka
Affiliations

Affiliation

  • 1 Drug Discovery, Johnson & Johnson Pharmaceutical Research and Development, L.L.C., 1000 Route 202, Raritan, NJ 08869, USA. krupert@prdus.jnj.com
PMID: 12565927 DOI: 10.1016/s0960-894x(02)01020-x
Abstract

The MAP kinase p38 is implicated in the release of the pro-inflammatory cytokines TNF-alpha and IL-1 beta. Inhibition of cytokine release may be a useful treatment for inflammatory conditions such as rheumatoid arthritis and Crohn's disease. A novel series of imidazopyrimidines have been discovered that potently inhibit p38 and suppress the production of TNF-alpha in vivo.

Figures
Products